Aliya Khan presented Phase 3 trial data at ENDO 2025.
2 reports, 1 independent
Updated Jul 15
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Aliya Khan presented Phase 3 trial data at ENDO 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Aliya Khan
researcher
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireNew 3-Year Phase 3 Data Confirmed Sustained Response to TransCon® PTH (Palopegteriparatide) Therapy in Adults with Hypoparathyroidism, Including Improvements in Biochemistries, Kidney Function, and Qu
- Unknown outlet